Colorectal cancer future or investigational therapies
|
Colorectal cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Colorectal cancer future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Colorectal cancer future or investigational therapies |
|
FDA on Colorectal cancer future or investigational therapies |
|
CDC on Colorectal cancer future or investigational therapies |
|
Colorectal cancer future or investigational therapies in the news |
|
Blogs on Colorectal cancer future or investigational therapies |
|
Risk calculators and risk factors for Colorectal cancer future or investigational therapies |
Editor(s)-in-Chief: C. Michael Gibson, M.S.,M.D. [1] Phone:617-632-7753; Elliot B. Tapper, M.D., Beth Israel Deaconess Medical Center
Overview
Vaccine
In November 2006, it was announced that a vaccine had been developed and tested with very promising results.[1] The new vaccine, called TroVax, works in a totally different way to existing treatments by harnessing the patient's own immune system to fight the disease. Experts say this suggests that gene therapy vaccines could prove an effective treatment for a whole range of cancers. Oxford BioMedica is a British spin-out from Oxford University specializing in the development of gene-based treatments. Phase III trials are underway for renal cancers and planned for colon cancers.[2]